Legler U F, Apple D J, Assia E I, Bluestein E C, Castaneda V E, Mowbray S L
Department of Ophthalmology, Medical University of South Carolina, Charleston 29425.
J Cataract Refract Surg. 1993 Jul;19(4):462-70. doi: 10.1016/s0886-3350(13)80609-8.
We investigated the effect of colchicine in a sustained drug delivery system on posterior capsule opacification (PCO) in rabbit eyes. A polymer matrix wafer, which diffused colchicine at a steady rate, was implanted in the capsular bag of 34 eyes after the lens material was removed by endocapsular phacoemulsification. Three different drug concentrations were used in the rabbit eyes, which were compared with control eyes containing the polymer matrix wafer without colchicine. The mean PCO score was highest in the control group without colchicine and increased steadily over 12 weeks. The rate of PCO formation in all eyes treated with colchicine was significantly lower than in the control group. There was no statistically significant improvement in PCO inhibition with the higher colchicine dosages. Side effects included inflammatory anterior chamber reaction and corneal and retinal complications and were most notable with the highest drug concentration. Slow release of colchicine reduces PCO formation in the rabbit. The optimal biocompatible dosage must be carefully determined and warrants further investigation.
我们研究了秋水仙碱缓释给药系统对兔眼后囊膜混浊(PCO)的影响。在通过囊内超声乳化摘除晶状体物质后,将以稳定速率扩散秋水仙碱的聚合物基质薄片植入34只眼睛的囊袋中。在兔眼中使用了三种不同的药物浓度,并与含有不含秋水仙碱的聚合物基质薄片的对照眼进行比较。在不含秋水仙碱的对照组中,平均PCO评分最高,且在12周内稳步上升。所有接受秋水仙碱治疗的眼睛中PCO形成的速率均显著低于对照组。较高剂量的秋水仙碱在抑制PCO方面并无统计学上的显著改善。副作用包括前房炎症反应以及角膜和视网膜并发症,在最高药物浓度时最为明显。秋水仙碱的缓释可减少兔眼中PCO的形成。必须仔细确定最佳生物相容性剂量,并值得进一步研究。